Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CTI BIOPHARMA CORP (CTI)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | | | | |
| Cost of goods sold | 6.5% | 7.1% | 8.2% | 12.1% | | | | |
| Gross profit | 93.5% | 92.9% | 91.8% | 87.9% | | | | |
| Selling, general and administrative | | 261.2% | 533.3% | 2902.7% | | | | |
| Research and development | 68.4% | 108.5% | 254.0% | 1644.4% | | | | |
| General and administrative | 43.9% | | | | | | | |
| Depreciation | 3.6% | 4.7% | 7.9% | 30.8% | | | | |
| EBIT | -147.9% | -309.1% | -770.9% | -4939.5% | | | | |
| Pre-tax income | -172.4% | -341.8% | -826.0% | -5133.6% | | | | |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | | | | |
| Net income | -172.4% | -341.8% | -826.0% | -5133.6% | | | | |
|